Biogen Inc. — FY 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone Q4 report; selected unaudited fourth-quarter results are also summarized below. Dollar amounts are in millions unless otherwise stated.
Business context
Biogen is a global biopharmaceutical company focused primarily on neurological and neurodegenerative diseases. Its marketed portfolio includes multiple sclerosis therapies, SPINRAZA for spinal muscular atrophy, biosimilars, and financial interests in Genentech’s anti-CD20 programs, including OCREVUS. Revenue remains substantially dependent on established products and collaboration economics while the company invests in its pipeline.
Financial results and liquidity
| Metric | FY 2020 | FY 2019 | Change |
|---|---|---|---|
| Total revenue | $13,444.6 | $14,377.9 | -6.5% |
| Operating income | $4,550.1 | $7,042.6 | -35.4% |
| Net income attributable to Biogen | $4,000.6 | $5,888.5 | -32.1% |
| Diluted EPS | $24.80 | $31.42 | -21.1% |
| Net cash from operating activities | $4,229.8 | $7,078.6 | -40.2% |
| Cash, cash equivalents and marketable securities at year-end | $3,382.2 | $5,884.0 | -42.5% |
| Notes payable at year-end | $7,426.2 | $5,954.8 | +24.7% |
| Working capital at year-end | $3,144.9 | $3,518.0 | -10.6% |
Operating margin was approximately 33.9% versus 49.0% in 2019. Net margin attributable to Biogen was approximately 29.8% versus 41.0%. Gross profit, as defined in the filing, was $11,639.4 million, or approximately 86.6% of revenue, compared with $12,422.5 million, or approximately 86.4%, in 2019.
FY 2020 investment cash flow was a use of $608.6 million; financing cash flow was a use of $5,272.7 million. Biogen repurchased approximately $6.7 billion of shares, issued $3.0 billion of senior notes, and redeemed $1.5 billion of notes. Year-end notes payable less cash and marketable securities implies net debt of approximately $4.0 billion. The company reported a $1.0 billion undrawn revolving credit facility and stated that existing funds, operating cash flow and financing access should cover foreseeable requirements.
Material changes versus comparable periods
- Product revenue fell 6.0% to $10,692.2 million. U.S. revenue fell 12.1%, partly offset by 2.7% growth in the rest of the world.
- MS revenue declined 8.2% to $7,832.1 million. Fumarate revenue fell 12.0% to $3,905.4 million, mainly due to U.S. TECFIDERA generic competition; interferon revenue fell 10.7%. TYSABRI revenue increased 2.8%.
- SPINRAZA revenue fell 2.1% to $2,052.1 million, with U.S. declines from competition and COVID-related site-of-care disruption partly offset by international growth.
- Anti-CD20 program revenue fell 13.6% to $1,977.8 million, primarily as U.S. RITUXAN biosimilar competition reduced revenue; OCREVUS royalties rose 23.0% to $845.4 million.
- Biosimilar revenue grew 7.8% to $795.8 million. Other revenue rose 9.5% to $774.6 million, including $346.2 million recognized under a manufacturing intellectual-property license and supply arrangement.
- Operating expenses rose 21.3%, driven mainly by $1,893.3 million in upfront collaboration-related R&D charges for Sage, Denali and Sangamo. R&D expense increased 75.0% to $3,990.9 million.
- Other income included $681.8 million of unrealized gains on equity investments, principally Denali and Sangamo. A $92.5 million gain related to the Hillerød divestiture estimate also reduced expenses.
Q4 snapshot: Revenue was $2,852.6 million versus $3,671.3 million in Q4 2019; net income attributable to Biogen was $357.9 million versus $1,439.7 million; diluted EPS was $2.32 versus $8.08.
Outlook, commentary and risks
- No quantified company-wide 2021 revenue or EPS guidance is provided in the supplied filing text. Management expected U.S. TECFIDERA generic competition to continue materially reducing sales and operating cash flow.
- Management expected 2021 interferon revenue to decline, TYSABRI volume to rise modestly, VUMERITY sales volume to increase, and biosimilar revenue to grow modestly to moderately, subject to COVID-19 effects. SPINRAZA faced increased competition, lower new-patient starts and COVID-related treatment delays.
- Management expected core R&D expense to increase in 2021 and SG&A costs to increase significantly as the company prepared for potential aducanumab launches.
- Aducanumab’s FDA application had an updated action date of June 7, 2021 after a three-month review extension. A majority of the FDA advisory committee voted against each question presented on the application. Approval and commercial success remained uncertain; $93.8 million of pre-launch inventory had been capitalized.
- Other risks include pricing and reimbursement pressure, product concentration, generic and biosimilar competition, clinical and regulatory uncertainty, patent litigation, third-party manufacturing and supply dependence, foreign exchange, and COVID-19 effects on demand, trials and operations.
- TECFIDERA patent judgments went against Biogen in U.S. proceedings and were under appeal. Several patent and other legal disputes remained pending; the filing states that possible losses in certain cases could not be estimated clearly.
- Biogen reported up to approximately $10.2 billion of potential future development, regulatory and commercial milestone payments, contingent on milestones being achieved. Its Solothurn facility was expected to be partially operational in the first half of 2021; timing and utilization risks were disclosed.
Important facts for investors to verify
- Whether TECFIDERA generic erosion, related patent appeals and deferred-tax-asset assumptions produce further revenue, cash-flow or tax impacts.
- FDA and other regulatory outcomes for aducanumab, potential launch costs, and the effect of any approval or rejection on earnings and cash flow.
- Actual commercial trends for SPINRAZA, TYSABRI, VUMERITY, OCREVUS-related royalties and biosimilars versus management’s stated expectations.
- How much of earnings and liquidity reflects recurring operations versus investment gains, collaboration charges, license revenue and other unusual items.
- Progress, cost and utilization of the Solothurn facility, and the company’s ability to service debt while funding R&D, milestones and capital returns.
- Potential financial exposure from pending litigation, contractual commitments and collaboration milestone obligations.